Skip to main content

Advertisement

Table 1 Demographic, clinical, and immunological data in association with the ARV treatment regimens

From: Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus – 1 (HIV-1) infected pediatric patients: a cross-sectional study

Parameters ARV treatment regimens
  NRTI+NNRTI+PI (n = 15) NRTI+NNRTI (n = 6) NRTI + PI (n = 13) NRTIs (n = 7)
Age of study entry (Mean+/-SD, yrs) 11.9+/-4.3 10.8+/-3.4 8.8+/-5.1 10.4+/-3.0
Length of treatment (Mean+/-SD, yrs) 7.8+/-3.1 6.7+/-2.3 5.1+/-2.8 5.8+/-2.7
Number of Medications     
NRTI 3.7+/-0.7 3.3+/-1.0 3.1+/-1.0 2.7+/-1.1
NNRTI 1.1 +/-0.2 1.2+/-0.4 - -
PI 1.1+/-0.6 - 1.2+/-0.4 -
Clinical categories *     
B 8 (53.3%) 3/5 (60.0%) 4 (30.8%) 3 (42.9%)
C 7 (46.7%) 2/5 (40.0%) 9(69.2%) 4 (57.1%)
Immune categories **     
1 (no suppression) 10 (66.3%) 4 (66.7%) 7 (53.9%) 3 (42.9%)
2–3 (moderate/severe) 7 (33.3%) 2 (33.3%) 6 (46.1%) 4 (57.1%)
PVL (n, %)     
<10,000 5 (33.3%) 4 (66.7%) 2 (15.4%) 4 (57.1%)
≥ 10,000 10 (66.7%) 2 (33.3%) 11 (84.6%) 3 (42.9%)
Number of mutations (Mean+/-SD) 5.7+/-3.8 3.5+/-1.6 4.7+/-3.2 3.7+/-2.3
  1. *B-moderately, C-severely symptomatic 22,23
  2. ** Immune categories based on age-specific CD4+ T-lymphocyte count.22,23